Country: Canada
Language: English
Source: Health Canada
LANTHANUM (LANTHANUM CARBONATE DIHYDRATE)
NATCO PHARMA (CANADA) INC
V03AE03
LANTHANUM CARBONATE
250MG
TABLET (CHEWABLE)
LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 250MG
ORAL
15G/50G
Prescription
PHOSPHATE-REMOVING AGENTS
Active ingredient group (AIG) number: 0151709001; AHFS:
APPROVED
2020-05-14
_NAT-LANTHANUM Product Monograph _ _Page 1 of 33 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR NAT-LANTHANUM Lanthanum carbonate dihydrate chewable tablets Chewable tablets, 250 mg, 500 mg, 750 mg, and 1000 mg, oral Phosphate binder Natco Pharma (Canada) Inc. Date of Initial Authorization: 2000 Argentia Road, Plaza 1, Suite 200 April 30, 2020 Mississauga, Ontario L5N 1P7 Date of Revision: August 24, 2023 Submission Control No: 275728 _ _ _NAT-LANTHANUM Product Monograph _ _Page 2 of 33 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Gastrointestinal 08/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES…………………………………………………………………………………………. 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations ............................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ....................................................... 4 4.4 Administration ........................................................................................................ 5 4 Read the complete document